Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. Among authors: kanter j. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
Styles L, Heiselman D, Heath LE, Moser BA, Small DS, Jakubowski JA, Zhou C, Redding-Lallinger R, Heeney MM, Quinn CT, Rana SR, Kanter J, Winters KJ. Styles L, et al. Among authors: kanter j. J Pediatr Hematol Oncol. 2015 Jan;37(1):1-9. doi: 10.1097/MPH.0000000000000291. J Pediatr Hematol Oncol. 2015. PMID: 25493452 Clinical Trial.
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators. Heeney MM, et al. Among authors: kanter j. N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8. N Engl J Med. 2016. PMID: 26644172 Free article. Clinical Trial.
Crizanlizumab in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J. Ataga KI, et al. Among authors: kanter j. N Engl J Med. 2017 May 4;376(18):1796. doi: 10.1056/NEJMc1703162. N Engl J Med. 2017. PMID: 28467874 No abstract available.
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. Niihara Y, et al. Among authors: kanter j. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. N Engl J Med. 2018. PMID: 30021096 Free article. Clinical Trial.
471 results